Piperlongumine, a novel treatment option to overcome BRAF inhibitor resistance in melanoma

被引：0
|
作者：
Ramachandran, Sharavan [1 ]
Fofaria, Neel [1 ]
Srivastava, Sanjay [1 ]
机构：
[1] Texas Tech Univ, Hlth Sci Ctr, Amarillo, TX USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-3518
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3518
引用
收藏
页数：2
相关论文
共 50 条
  • [21] BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model
    Perna, Daniele
    Karreth, Florian A.
    Rust, Alistair G.
    Perez-Mancera, Pedro A.
    Rashid, Mamunur
    Iorio, Francesco
    Alifrangis, Constantine
    Arends, Mark J.
    Bosenberg, Marcus W.
    Bollag, Gideon
    Tuveson, David A.
    Adams, David J.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2015, 112 (06) : E536 - E545
  • [22] Novel mechanisms of resistance in BRAF-mutant melanoma
    Poulikakos, Poulikos I.
    CLINICAL CANCER RESEARCH, 2012, 18 (10)
  • [23] Combination with γ-secretase inhibitor prolongs treatment efficacy of BRAF inhibitor in BRAF-mutated melanoma cells
    Schrama, D.
    Zhu, G.
    Goebeler, M.
    Houben, R.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2016, 14 : 26 - 27
  • [24] Combination with γ-secretase inhibitor prolongs treatment efficacy of BRAF inhibitor in BRAF-mutated melanoma cells
    Schrama, D.
    Zhu, G.
    Goebeler, M.
    Houben, R.
    EXPERIMENTAL DERMATOLOGY, 2017, 26 (03) : E93 - E93
  • [25] Combination with γ-secretase inhibitor prolongs treatment efficacy of BRAF inhibitor in BRAF-mutated melanoma cells
    Zhu, Guannan
    Yi, Xiuli
    Haferkamp, Sebastian
    Hesbacher, Sonja
    Li, Chunying
    Goebeler, Matthias
    Gao, Tianwen
    Houben, Roland
    Schrama, David
    CANCER LETTERS, 2016, 376 (01) : 43 - 52
  • [26] Combination with gamma secretase inhibitor prolongs treatment efficacy of BRAF inhibitor in BRAF mutant melanoma cells
    Zhu, G.
    Yi, X.
    Haferkamp, S.
    Hesbacher, S.
    Li, C.
    Goebeler, M.
    Gao, T.
    Houben, R.
    Schrama, D.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2016, 136 (05) : S116 - S116
  • [27] Intermittent BRAF-inhibitor therapy is a feasible option: report of a patient with metastatic melanoma
    Koop, A.
    Satzger, I.
    Alter, M.
    Kapp, A.
    Hauschild, A.
    Gutzmer, R.
    BRITISH JOURNAL OF DERMATOLOGY, 2014, 170 (01) : 220 - 222
  • [28] Targeting melanoma metabolism to overcome resistance to treatment.
    Betoff, Allison
    Zippin, Jonathan
    Merghoub, Taha
    Chapman, Paul B.
    Wolchok, Jedd
    CANCER RESEARCH, 2020, 80 (19)
  • [29] Overcoming the resistance to BRAF inhibitor by the double BRAF and MEK inhibitions in advanced melanoma: a case report
    Kattan, Joseph
    Kattan, Clarisse
    Farhat, Fadi
    Assi, Tarek
    ANTI-CANCER DRUGS, 2019, 30 (10) : 1052 - 1054
  • [30] Upregulation of MicroRNA-1246 Is Associated with BRAF Inhibitor Resistance in Melanoma Cells with Mutant BRAF
    Kim, Jae-Hyeon
    Ahn, Jun-Ho
    Lee, Michael
    CANCER RESEARCH AND TREATMENT, 2017, 49 (04): : 947 - 959
12345